For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.

TitleAntiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.
Publication TypeJournal Article
Year of Publication2008
AuthorsKlasse PJohan, Shattock R, Moore JP
JournalAnnu Rev Med
Volume59
Pagination455-71
Date Published2008
ISSN0066-4219
KeywordsAnti-Retroviral Agents, Female, HIV Infections, HIV-1, Humans, Male, Vaginal Creams, Foams, and Jellies
Abstract

The development of a vaginal (and perhaps a rectal) microbicide would be of major benefit for slowing the global spread of human immunodeficiency virus type 1 (HIV-1). A microbicide is a gel or related device that, when inserted vaginally or rectally, acts to prevent infection of a woman or a man by HIV-1 during sexual intercourse. A practical microbicide must be not only effective, safe, and user-friendly but also economically affordable in the developing world. To date, the performance of microbicide candidates in efficacy trials has been disappointing, but next-generation concepts now in or approaching clinical trials offer improved prospects for efficacy. The most plausible approaches involve topical application of antiretroviral agents with specific activity against HIV-1, compounds similar to drugs used to treat HIV-1 infection. How these inhibitors are applied may also be critical, with sustained-release formulations and vaginal ring delivery systems now becoming a high priority.

DOI10.1146/annurev.med.59.061206.112737
Alternate JournalAnnu. Rev. Med.
PubMed ID17892435
Grant ListU19 AI 65413 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587